The IVISbrite™ HepG2 Red F-luc tumor cell line (Bioware® Brite HepG2-Red-FLuc) is a light-producing cell line derived from HepG2 human hepatocellular carcinoma. The cells have been stably transduced with the red-shifted firefly luciferase gene from Luciola Italica (Red F-luc), for a brighter, red-shifted signal.
For research use only. Not for use in diagnostic procedures.
The IVISbrite™ HepG2 Red F-luc tumor cell line (Bioware® Brite HepG2-Red-FLuc) is a light-producing cell line derived from HepG2 human hepatocellular carcinoma. The cells have been stably transduced with the red-shifted firefly luciferase gene from Luciola Italica (Red F-luc), for a brighter, red-shifted signal.
For research use only. Not for use in diagnostic procedures.
IVISbrite HepG2 Red F-luc Bioluminescent Tumor Cell line
This cell line has very bright bioluminescence, emitting at least 35,000 photons/cell/sec in vitro. The exact number will vary depending on imaging and culturing conditions.
By emitting intensified, longer wavelength light that is significantly brighter than other firefly luciferases, our bioluminescent oncology cell lines allow you to visualize and monitor the growth of deep tissue tumors in vivo.
After the cells are injected into an appropriate mouse model, the optimized Red F-luc luciferase enables more sensitive in vivo optical detection with less tissue attenuation so you can detect tumor development earlier, and monitor tumor growth and metastases in both subcutaneous and orthotopic models.
Brand |
IVISbrite
|
---|---|
Cancer Model |
Liver
|
Imaging Modality |
Bioluminenscence
|
Luciferase Classification |
Firefly
|
Shipping Conditions |
Shipped in Dry Ice
|
Unit Size |
2 vials each containing 1 million cells
|
Are you looking for resources, click on the resource type to explore further.
The application note demonstrates how our IVISbrite tumor cell lines labeled with red-shifted luciferase (Red F-luc) yields a 100...
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and...
We are here to answer your questions.